APOE基因常见遗传变异与急性髓系白血病移植后结局
该研究对两个当代队列共348例和447例接受异基因造血干细胞移植的急性髓系白血病患者进行APOE基因分型,评估受者与供者APOE遗传变异与移植后结局的关联。携带至少1个APOE2等位基因的患者移植后死亡风险高于APOE4携带者,发现队列HR 2.09(P=0.024),验证队列HR 1.96(P=0.040)。APOE2的不良效应由严重慢性移植物抗宿主病(GVHD;校正HR 1.85,P=0.034)和非复发死亡(校正HR 1.72,P=0.044)风险增加驱动。在非APOE2受者中,移植APOE2阳性移植物与APOE2阴性移植物相比,3至4级急性GVHD(校正HR 2.82,P=0.012)和严重慢性GVHD(校正HR 2.54,P=0.022)发生率增加。总之,APOE2等位基因在普通人群中通常被视为长寿基因,但当存在于宿主或由供者移植时,与急性GVHD(校正HR 2.75,P=0.002)、慢性GVHD(校正HR 2.57,P=0.001)和移植后死亡(校正HR 1.79,P=0.004)风险增高相关。
要点
- 携带至少1个APOE2等位基因的受者移植后死亡风险高于APOE4携带者,发现队列HR 2.09(P=0.024),验证队列HR 1.96(P=0.040)。
- APOE2的不良效应由严重慢性GVHD(校正HR 1.85,P=0.034)和非复发死亡(校正HR 1.72,P=0.044)风险增加驱动。
- 在非APOE2受者中,APOE2阳性移植物与3至4级急性GVHD(校正HR 2.82,P=0.012)和严重慢性GVHD(校正HR 2.54,P=0.022)风险增加相关。
核心结论
- APOE2等位基因在普通人群中通常被视为长寿基因,但当存在于宿主或由供者移植时,与急性GVHD(校正HR 2.75,P=0.002)、慢性GVHD(校正HR 2.57,P=0.001)和移植后死亡(校正HR 1.79,P=0.004)风险增高相关。
研究设计与样本
- 对两个当代队列分别纳入348例和447例接受异基因造血干细胞移植的急性髓系白血病患者进行APOE基因分型,评估受者与供者APOE遗传变异与移植后结局的关联。
主要发现
- 携带至少1个APOE2等位基因的患者移植后死亡风险高于APOE4携带者,发现队列HR 2.09(P=0.024),验证队列HR 1.96(P=0.040)。
- APOE2的不良效应由严重慢性GVHD(校正HR 1.85,P=0.034)和非复发死亡(校正HR 1.72,P=0.044)风险增加驱动。
- 在非APOE2受者中,移植APOE2阳性移植物与APOE2阴性移植物相比,3至4级急性GVHD(校正HR 2.82,P=0.012)和严重慢性GVHD(校正HR 2.54,P=0.022)发生率增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germ line variants APOE2, APOE3, and APOE4 give rise to 3 functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied. We performed APOE genotyping in 2 contemporary cohorts of 348 and 447 patients with acute myeloid leukemia who had received allogeneic HSCT and evaluated the associations of recipient and donor APOE genetic variations with posttransplant outcomes. Patients who carried at least 1 APOE2 allele had a higher risk of posttransplant death than APOE4 carriers in the discovery (hazard ratio [HR], 2.09; P = .024) and validation cohorts (HR, 1.96; P = .040). Detrimental APOE2 effects were driven by an increased risk of severe chronic graft-versus-host disease (GVHD; adjusted HR [HRadj], 1.85; P = .034) and nonrelapse death (HRadj, 1.72; P = .044). In non-APOE2 recipients, transplantation of an APOE2-positive allograft was associated with an increased incidence of grade 3 to 4 acute GVHD (HRadj, 2.82; P = .012) and severe chronic GVHD (HRadj, 2.54; P = .022) compared with APOE2-negative grafts. In summary, the APOE2 allele, typically considered a longevity gene in the general population, was associated with a higher risk of acute GVHD (HRadj, 2.75; P = .002), chronic GVHD (HRadj, 2.57; P = .001), and posttransplant mortality (HRadj, 1.79; P = .004), when present in either the host or transplanted from the donor.
引用
- Ronnacker J, Grau M, Klasmeier M, et al. Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia. Blood. 2025. PMID: 39813679. doi:10.1182/blood.2024026886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。